Novel Oral AntiCoagulants (NOAC) Market Report

Global and Region Novel Oral AntiCoagulants (NOAC) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：225
  • REPORT CODE：GMM949975
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Novel Oral AntiCoagulants (NOAC) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Novel Oral AntiCoagulants (NOAC)market, defines the market attractiveness level of Novel Oral AntiCoagulants (NOAC) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Novel Oral AntiCoagulants (NOAC) industry, describes the types of Novel Oral AntiCoagulants (NOAC) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Novel Oral AntiCoagulants (NOAC) market and the development prospects and opportunities of Novel Oral AntiCoagulants (NOAC) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Novel Oral AntiCoagulants (NOAC) market in Chapter 13.

    By Player:

    • Boehringer Ingelheim

    • Cosmo Pharmaceuticals

    • CSL Behring

    • AstraZeneca

    • Bayer

    • Sanofi

    • Aspen

    • Cellceutix

    • Daiichi Sankyo

    • Perosphere

    • GSK

    • Johnson & Johnson

    • Bristol-Myers Squibb

    • Marathon Pharmaceuticals

    • Eisai

    • Armatheon

    • Ockham Biotech

    By Type:

    • Direct Thrombin Inhibitors

    • Direct Factor Xa Inhibitors

    By End-User:

    • Deep Vein Thrombosis (DVT)

    • Pulmonary Embolism

    • Acute Coronary Syndrome

    • Hemodialysis

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Novel Oral AntiCoagulants (NOAC) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Novel Oral AntiCoagulants (NOAC) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Novel Oral AntiCoagulants (NOAC) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Novel Oral AntiCoagulants (NOAC) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Novel Oral AntiCoagulants (NOAC) Market Analysis and Outlook to 2022

    • 7.1 Global Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.2 United States Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.3 Europe Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.4 China Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.5 Japan Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.6 India Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    • 7.7 South Korea Novel Oral AntiCoagulants (NOAC) Consumption (2017-2022)

    8 Region and Country-wise Novel Oral AntiCoagulants (NOAC) Market Analysis and Outlook to 2028

    • 8.1 Global Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.2 United States Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.3 Europe Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.4 China Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.5 Japan Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.6 India Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    • 8.7 South Korea Novel Oral AntiCoagulants (NOAC) Consumption Forecast (2022-2028)

    9 Global Novel Oral AntiCoagulants (NOAC) Market Outlook by Types and Applications to 2022

    • 9.1 Global Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Direct Thrombin Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Direct Factor Xa Inhibitors Consumption and Growth Rate (2017-2022)

    • 9.2 Global Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Deep Vein Thrombosis (DVT) Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pulmonary Embolism Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Acute Coronary Syndrome Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Hemodialysis Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Novel Oral AntiCoagulants (NOAC) Market Outlook by Types and Applications to 2028

    • 10.1 Global Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Direct Thrombin Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Direct Factor Xa Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Deep Vein Thrombosis (DVT) Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Pulmonary Embolism Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Acute Coronary Syndrome Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Hemodialysis Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Novel Oral AntiCoagulants (NOAC) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Novel Oral AntiCoagulants (NOAC) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Novel Oral AntiCoagulants (NOAC) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Novel Oral AntiCoagulants (NOAC) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Novel Oral AntiCoagulants (NOAC) Market Competitive Analysis

    • 14.1 Boehringer Ingelheim

      • 14.1.1 Boehringer Ingelheim Company Details

      • 14.1.2 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.2 Cosmo Pharmaceuticals

      • 14.2.1 Cosmo Pharmaceuticals Company Details

      • 14.2.2 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.3 CSL Behring

      • 14.3.1 CSL Behring Company Details

      • 14.3.2 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.4 AstraZeneca

      • 14.4.1 AstraZeneca Company Details

      • 14.4.2 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.5 Bayer

      • 14.5.1 Bayer Company Details

      • 14.5.2 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Bayer Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.6 Sanofi

      • 14.6.1 Sanofi Company Details

      • 14.6.2 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Sanofi Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.7 Aspen

      • 14.7.1 Aspen Company Details

      • 14.7.2 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Aspen Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.8 Cellceutix

      • 14.8.1 Cellceutix Company Details

      • 14.8.2 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.9 Daiichi Sankyo

      • 14.9.1 Daiichi Sankyo Company Details

      • 14.9.2 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.10 Perosphere

      • 14.10.1 Perosphere Company Details

      • 14.10.2 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Perosphere Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.11 GSK

      • 14.11.1 GSK Company Details

      • 14.11.2 GSK Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 GSK Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.12 Johnson & Johnson

      • 14.12.1 Johnson & Johnson Company Details

      • 14.12.2 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.13 Bristol-Myers Squibb

      • 14.13.1 Bristol-Myers Squibb Company Details

      • 14.13.2 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.14 Marathon Pharmaceuticals

      • 14.14.1 Marathon Pharmaceuticals Company Details

      • 14.14.2 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.15 Eisai

      • 14.15.1 Eisai Company Details

      • 14.15.2 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Eisai Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.16 Armatheon

      • 14.16.1 Armatheon Company Details

      • 14.16.2 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Armatheon Novel Oral AntiCoagulants (NOAC) Product and Service

    • 14.17 Ockham Biotech

      • 14.17.1 Ockham Biotech Company Details

      • 14.17.2 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Novel Oral AntiCoagulants (NOAC)

    • Figure Novel Oral AntiCoagulants (NOAC) Picture

    • Table Global Novel Oral AntiCoagulants (NOAC) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Novel Oral AntiCoagulants (NOAC) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Novel Oral AntiCoagulants (NOAC) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Novel Oral AntiCoagulants (NOAC) Consumption by Country (2017-2022)

    • Figure United States Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Table Europe Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Figure China Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Figure Japan Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Figure India Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Novel Oral AntiCoagulants (NOAC) Consumption and Growth Rate (2017-2022)

    • Figure Global Novel Oral AntiCoagulants (NOAC) Consumption Forecast by Country (2022-2028)

    • Figure United States Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Novel Oral AntiCoagulants (NOAC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Direct Thrombin Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Direct Factor Xa Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Deep Vein Thrombosis (DVT) Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Embolism Consumption and Growth Rate (2017-2022)

    • Figure Global Acute Coronary Syndrome Consumption and Growth Rate (2017-2022)

    • Figure Global Hemodialysis Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Direct Thrombin Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Direct Factor Xa Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Deep Vein Thrombosis (DVT) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pulmonary Embolism Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Acute Coronary Syndrome Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hemodialysis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Novel Oral AntiCoagulants (NOAC) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Novel Oral AntiCoagulants (NOAC) Export by Region (Top 5 Countries) (2017-2028)

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Cosmo Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table CSL Behring (Foundation Year, Company Profile and etc.)

    • Table CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Behring Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Aspen (Foundation Year, Company Profile and etc.)

    • Table Aspen Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aspen Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Cellceutix (Foundation Year, Company Profile and etc.)

    • Table Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cellceutix Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Perosphere (Foundation Year, Company Profile and etc.)

    • Table Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Perosphere Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table GSK (Foundation Year, Company Profile and etc.)

    • Table GSK Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Marathon Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Eisai (Foundation Year, Company Profile and etc.)

    • Table Eisai Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Armatheon (Foundation Year, Company Profile and etc.)

    • Table Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Armatheon Novel Oral AntiCoagulants (NOAC) Product and Service

    • Table Ockham Biotech (Foundation Year, Company Profile and etc.)

    • Table Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US